<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858572</url>
  </required_header>
  <id_info>
    <org_study_id>9090-03</org_study_id>
    <nct_id>NCT00858572</nct_id>
  </id_info>
  <brief_title>STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders</brief_title>
  <official_title>A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib)
      in subjects with hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the safety and tolerability of STA-9090 (ganetespib) in subjects with hematologic malignancies</measure>
    <time_frame>Feb 2011</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess preliminary evidence of anti-neoplastic activity</measure>
    <time_frame>Feb 2011</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the pharmacokinetics of STA-9090 (ganetespib) when administered as a short-term intravenous infusion</measure>
    <time_frame>Feb 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess changes in biomarkers following study drug administration</measure>
    <time_frame>Feb 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate drug exposure levels/plasma concentrations and correlations with efficacy and safety parameters</measure>
    <time_frame>Feb 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of variations in drug metabolizing enzymes (DME pharmacogenomics) on the pharmacokinetics of STA-9090 (ganetespib)</measure>
    <time_frame>Feb 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>AML</condition>
  <condition>CML</condition>
  <condition>MDS</condition>
  <condition>Myeloproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA-9090 (ganetespib)</intervention_name>
    <description>Chemotherapy agent</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Males and females 18 years or older

          -  Eligible subjects must have one of the following relapsed or refractory hematologic
             malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the
             protocol

          -  Must have acceptable organ function during screening as defined in the protocol

        Exclusion Criteria

          -  Pregnant or breast-feeding women

          -  Patients must meet the washout periods for prior chemotherapies and radiation

          -  History of stroke within 6 months of treatment

          -  Poor venous access for study drug administration

          -  Treatment with chronic immunosuppressants

          -  Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality
             that may increase the risk associated with study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Synta</keyword>
  <keyword>STA-9090</keyword>
  <keyword>AML</keyword>
  <keyword>CML</keyword>
  <keyword>MDS</keyword>
  <keyword>myeloproliferative disorder</keyword>
  <keyword>hematologic malignancy</keyword>
  <keyword>ganetespib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

